Skip to content

Study · Animal study (in vivo) · mouse · 2016

3 results

Selank Inhibits Ethanol-Induced Hyperlocomotion and Manifestation of Behavioral Sensitization in DBA/2 Mice.

Kolik LG, Nadorova AV, Seredenin SB

Bulletin of experimental biology and medicine23 Nov 2016Cited by 1 (Europe PMC)

PMID27878720 (opens in a new tab)DOI10.1007/s10517-016-3544-6 (opens in a new tab)PepBankPUB-27878720
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male DBA/2 mice, Selank at 0.3 mg/kg prevented the development of ethanol-induced hyperlocomotion.

    In plain wordsIn mice, Selank prevented the increase in movement that alcohol normally causes.

    Peptide
    Selank
    Outcome
    DecreaseDevelopment of ethanol-induced hyperlocomotion
    Study

    mousen: not reported in source

    Male DBA/2 mice, ethanol-induced hyperlocomotion and behavioral sensitization
    Comparator
    Naloxone; Afobazole
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    0.3 mg/kg · intraperitonealAs given in this study (mouse).

    Source sentences

    Summary
    Selank that enhances activity of the endogenous opioid system (0.3 mg/kg, intraperitoneally)
    2 context sentences
    Summary · context
    prevented the development of ethanol-induced (2.0 g/kg intraperitoneally) hyperlocomotion
    Summary · context
    The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male DBA/2 mice, a single dose of Selank significantly blocked the manifestation of ethanol motor sensitization.

    In plain wordsIn mice, one dose of Selank blocked the expression of alcohol-driven movement sensitization.

    Peptide
    Selank
    Outcome
    DecreaseManifestation of ethanol motor sensitization
    Study

    mousen: not reported in source

    Male DBA/2 mice, ethanol-induced hyperlocomotion and behavioral sensitization
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · single doseAs given in this study (mouse).

    Source sentences

    Summary
    Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation.
    1 context sentence
    Summary · context
    The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male DBA/2 mice, a single dose of Selank did not affect the formation of ethanol motor sensitization.

    In plain wordsIn mice, one dose of Selank did not stop alcohol-driven movement sensitization from forming.

    Peptide
    Selank
    Outcome
    No significant changeFormation of ethanol motor sensitization
    Study

    mousen: not reported in source

    Male DBA/2 mice, ethanol-induced hyperlocomotion and behavioral sensitization
    Outcome group
    Anxiety and mood · Nervous system and cognition
    Studied dose
    Dose not stated · intraperitoneal · single doseAs given in this study (mouse).

    Source sentences

    Summary
    Single dose of Selank significantly blocked manifestation of motor sensitization without affecting its formation.
    1 context sentence
    Summary · context
    The effect of non-benzodiazepine anxiolytics on the ethanol-induced hyperlocomotion and behavioral sensitization was assessed in male DBA/2 mice.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 19:08 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.